EMERGENCY:Any first presentation of severe unilateral headache with autonomic features (eye watering, nasal congestion) in a patient not previously diagnosed —call040-46324365immediately — 24 hours, 7 days— 24/7
Paroxysmal Hemicrania in Hyderabad: The Headache That Is Diagnosed and Cured by the Same Tablet
Expert TAC assessment, ICHD-3 differentiation from cluster headache and SUNCT/SUNA, the supervised indomethacin test for both diagnosis and treatment, dose escalation to 225mg/day where needed, GI and renal protection on long-term therapy, and COX-2/verapamil/topiramate/melatonin/greater occipital nerve block alternatives at KIMS Neuroscience, Secunderabad, Hyderabad.
Paroxysmal hemicrania (PH) is a rare primary headache disorder belonging to the trigeminal autonomic cephalalgias (TACs). It is defined by short-duration (2–30 minutes), severe, strictly unilateral orbital pain occurring with high frequency (5–40 attacks per day), with at least one ipsilateral cranial autonomic feature (lacrimation, ptosis, rhinorrhoea), and — most importantly — an absolute, complete response to indomethacin. The indomethacin response is part of the ICHD-3 diagnostic definition: a patient who does not have a complete response to indomethacin at up to 225mg/day does not have PH. This makes indomethacin both the diagnostic test and the treatment. PH affects women approximately 2:1 over men — unlike cluster headache, which is predominantly male.
- What it is
- TAC with 5–40 daily attacks of strictly unilateral orbital pain lasting 2–30 minutes, ipsilateral autonomic features, and absolute response to indomethacin.
- Sex predominance
- Female (~2:1). Distinguishes from cluster headache (male predominant, 3–5:1). Can occur at any age including childhood.
- The indomethacin test at KIMS
- Start 25mg TDS with food and PPI. Reassess at 72h. Escalate to 50mg TDS (150mg/day) then 75mg TDS (225mg/day) as needed. Complete cessation = diagnostic of PH; no response at 225mg/day excludes PH.
- Cluster vs PH at a glance
- Cluster: 15–180 min attacks, 1–8/day, male. PH: 2–30 min attacks, 5–40/day, female. Cluster responds to O₂/sumatriptan. PH responds absolutely to indomethacin (and not to O₂/sumatriptan).
- GI protection mandatory
- Long-term indomethacin: peptic ulceration risk. KIMS co-prescribes omeprazole 20–40mg. Take with food. Report epigastric pain, melena, or haematemesis immediately.
- Renal and BP monitoring
- Annual creatinine/eGFR and blood pressure on chronic indomethacin. Avoid in pre-existing renal impairment or significant cardiovascular disease. COX-2 inhibitor (celecoxib/etoricoxib) as alternative when GI intolerant.
- Contact KIMS
- 040-44885000 · TAC differentiation · Supervised indomethacin test · Long-term GI/renal monitoring · GON block when indomethacin not tolerated
| Fact | Details |
|---|---|
| Attack profile | Severe (7–10/10) · Strictly unilateral orbital/supraorbital/temporal · 2–30 minutes · 5–40 attacks/day · Ipsilateral lacrimation, ptosis, rhinorrhoea |
| Sex predominance | Female ~2:1 · Opposite of cluster headache (3–5:1 male) · Any age, including children and elderly |
| Indomethacin diagnostic | Absolute and complete response is part of ICHD-3 definition · Both diagnostic test and treatment · No other condition responds this completely |
| Indomethacin protocol at KIMS | Start 25mg TDS (75mg/day) · Reassess 72h · Escalate to 150mg/day then 225mg/day · No response at 225mg/day excludes PH |
| GI protection | PPI (omeprazole 20–40mg) co-prescribed at KIMS for every patient · Take indomethacin with food · Monitor for ulcer/bleeding symptoms |
| Renal/cardiovascular monitoring | Annual creatinine, eGFR, BP · Avoid in pre-existing renal impairment or significant CVD · COX-2 inhibitor as alternative when GI intolerant |
| Differential | Cluster (15–180 min, 1–8/day, male, no indomethacin) · SUNCT (1–600 sec, no indomethacin response, refractory period) · Hemicrania continua (continuous, indomethacin-responsive) |
About This Condition
Paroxysmal Hemicrania at a Glance
The essential facts that shape how PH is recognised, distinguished from cluster headache and other TACs, and managed at KIMS — from the high attack frequency and short duration to the pathognomonic absolute response to indomethacin that is both diagnostic test and cure.
What it is
Paroxysmal Hemicrania (PH) is a rare primary headache disorder belonging to the Trigeminal Autonomic Cephalalgias (TACs) — a group characterised by severe unilateral headache with ipsilateral cranial autonomic features. PH is defined by short-duration (2–30 minutes), severe, strictly unilateral orbital, supraorbital, or temporal pain occurring with high frequency (5–40 attacks per day), with at least one ipsilateral autonomic feature, and — most importantly — absolute, complete response to indomethacin.
The indomethacin response is diagnostic
The absolute and complete response to indomethacin is not merely characteristic of PH — it is part of the diagnostic definition. A patient who does not have a complete response to an adequate dose of indomethacin does not have paroxysmal hemicrania (they may have another TAC or secondary headache). This means that indomethacin both diagnoses and treats the condition simultaneously. At KIMS, the indomethacin test is performed as part of every TAC evaluation.
Who it affects
Rare: prevalence approximately 1–2 per 10,000. Female predominance (female:male approximately 2:1) — unlike cluster headache, which is predominantly male. Can occur at any age, including childhood and the elderly. Both episodic (with remission periods) and chronic (continuous, without significant remission) forms exist.
Distinguishing from cluster headache
PH and cluster headache can be clinically similar but differ critically in attack duration (PH: 2–30 minutes; cluster: 15–180 minutes), attack frequency (PH: 5–40 per day; cluster: 1–8 per day), sex predominance (PH female; cluster male), and treatment (indomethacin is diagnostic for PH; oxygen and triptans treat cluster; indomethacin does NOT treat cluster headache). Confusing the two leads to ineffective treatment.
Appointment
040-44885000
Twenty Attacks a Day, One Tablet to End Them
A 38-year-old woman in Hyderabad presents to KIMS with a headache pattern that has been going on for 8 months. She is having approximately 15–20 attacks per day of severe pain in and around her left eye. Each attack lasts 10–20 minutes. During the attack, her left eye waters and becomes red. Her left nostril runs. The pain is severe — she rates it 8–9/10. She cannot predict when attacks will come. They occur at any time of day, including waking her from sleep.
She has been seen by two neurologists. The first told her it was cluster headache and prescribed verapamil and oxygen. Neither has helped. The second prescribed sumatriptan, which she tried during several attacks without meaningful benefit.
At KIMS, the history is re-examined carefully against the TAC classification. The key distinguishing features emerge: 15–20 attacks per day (far more than the maximum 8 in cluster headache); each attack 10–20 minutes (shorter than the minimum 15 minutes usually seen in cluster, and certainly shorter than the 45–90 minute typical cluster attack); and female sex (cluster is predominantly male — the ratio in this woman’s presentation strongly favours PH). She has had no response to verapamil, oxygen, or sumatriptan — the specific cluster treatments.
The KIMS indomethacin test is performed: indomethacin 25mg three times daily with food. Within 36 hours, her attacks have stopped completely. She has zero attacks on day 3. She has had paroxysmal hemicrania all along — and indomethacin is simultaneously the diagnostic test and the cure.
Book a Consultation
Speak directly with our headache and TAC specialist team — ICHD-3 classification, supervised indomethacin testing, long-term GI/renal monitoring, and indomethacin-intolerant alternative pathways coordinated under one roof. No referral required. Monday to Saturday.
040-44885000Emergency line: 040-46324365Clinical Features of Paroxysmal Hemicrania
PH is defined by a combination of severe orbital unilateral pain, characteristically short attack duration with very high attack frequency, ipsilateral autonomic features, no refractory period between attacks (distinguishing from SUNCT), and the pathognomonic absolute response to indomethacin — each of which is specifically assessed at KIMS.
The pain — severe, orbital, unilateral
Severe (typically 7–10/10) unilateral pain in the orbital, supraorbital, or temporal region. Always strictly unilateral (same side for all attacks in a given patient). Quality: throbbing, boring, or stabbing. Onset is rapid, reaching peak intensity within minutes. Despite its severity, PH pain is slightly less extreme than cluster headache (which is consistently rated the maximum of human pain experience) — though still severely disabling.
Duration — short, 2 to 30 minutes
The defining duration characteristic: each attack lasts 2 to 30 minutes. Most attacks in a given patient last a fairly consistent duration within that range — e.g., always 5–10 minutes, or always 15–25 minutes. This short duration means attacks are over relatively quickly, but the sheer frequency (5–40 per day) means cumulative disability is enormous.
Frequency — high, 5 to 40 attacks per day
PH patients typically experience 5–40 attacks per day. This very high frequency is perhaps the most striking clinical feature, and is the key distinguishing feature from cluster headache (maximum 8 attacks per day, typically 1–4). Many PH patients have attacks occurring approximately every hour throughout the day and night.
Ipsilateral autonomic features — same as other TACs
At least one ipsilateral (same-side as pain) autonomic feature: lacrimation (eye watering), conjunctival injection (red eye), nasal congestion, rhinorrhoea, eyelid oedema, ptosis, miosis, or facial sweating. These features are identical to those of cluster headache and paroxysmal hemicrania — they reflect activation of the same trigeminal-autonomic reflex arc. They cannot be used to distinguish PH from cluster headache.
No refractory period — distinguishing from SUNCT
Unlike SUNCT/SUNA (another TAC with very short attacks of 1–600 seconds), PH attacks can be provoked repeatedly in quick succession with no refractory period between them. This distinguishes PH from SUNCT and is clinically useful when the attack duration is at the short end of the PH range.
Absolute indomethacin response — the diagnostic criterion
The complete and absolute prevention of attacks with therapeutic doses of indomethacin is the pathognomonic feature of PH. This means: not a partial response, not a reduction — a complete cessation of attacks. No other headache condition (including cluster headache, SUNCT, and migraine) responds in this absolute, complete, and rapid fashion to indomethacin. The mechanism of this selective response is not fully understood — indomethacin may reduce hypothalamic inflammation or have direct effects on nitric oxide and prostaglandin pathways that are specific to the PH mechanism.
Diagnosis at KIMS
Diagnosis at KIMS — The Indomethacin Test, Maintenance Dosing, and Long-Term Safety Monitoring
Starting dose and response assessment
Indomethacin 25mg with food, three times daily (75mg/day total). Reassess at 48–72 hours. A complete response — total cessation of attacks — at 75mg/day is diagnostic of PH. If there is no response at 72 hours, the dose is increased to 50mg three times daily (150mg/day) and reassessed at 72 hours. If still no response, indomethacin 75mg three times daily (225mg/day) is tried. A patient who does not respond at 225mg/day does not have paroxysmal hemicrania by ICHD-3 criteria.
Maintenance dosing
Once the effective dose is established, it is continued as the maintenance treatment. Many patients are well-controlled on 75–150mg/day long-term. The effective dose is established individually — the minimum dose that completely suppresses attacks. Some patients can eventually taper to a lower dose; others require indefinite treatment at their established dose.
Gastrointestinal protection — mandatory
Long-term indomethacin carries significant risks of gastrointestinal side effects: peptic ulceration, gastrointestinal haemorrhage, and dyspepsia. A proton pump inhibitor (omeprazole 20–40mg daily or equivalent) is co-prescribed at KIMS with indomethacin for every PH patient. Patients are counselled to take indomethacin with food, to report any epigastric pain, and to seek urgent review if they notice black stools (melena) or vomiting blood.
Renal monitoring
Long-term NSAID use can affect renal function. Annual renal function tests (serum creatinine, eGFR) at KIMS for all patients on chronic indomethacin. Blood pressure monitored as NSAIDs can cause fluid retention and mild blood pressure elevation. Indomethacin is avoided in patients with pre-existing renal impairment or significant cardiovascular disease.
Differential Diagnosis — Where PH Sits Among the TACs
The table on the Cluster Headache page provides the full TAC comparison (Cluster vs PH vs SUNCT/SUNA). The four key differentials below summarise the points that matter for clinical practice at KIMS — distinguishing PH from cluster headache and SUNCT/SUNA, separating PH from hemicrania continua, and excluding secondary structural causes with MRI brain at first presentation.
PH vs Cluster Headache
Duration (PH 2–30 min vs cluster 15–180 min); frequency (PH 5–40/day vs cluster 1–8/day); sex (PH female predominance vs cluster male predominance); indomethacin response (PH absolute vs cluster none). If attacks are shorter than 30 minutes and more frequent than 5 per day, test for PH first — indomethacin is safe and the response is unmistakable.
PH vs SUNCT/SUNA
Duration (PH 2–30 min vs SUNCT 1–600 seconds, usually very brief); frequency (similar); indomethacin (PH absolute response vs SUNCT no response); refractory period (PH none vs SUNCT present). SUNCT/SUNA attacks are typically much briefer — seconds rather than minutes — and do not respond to indomethacin.
PH vs Hemicrania Continua
Hemicrania continua is a continuous (not paroxysmal) unilateral headache that also responds absolutely to indomethacin. If the headache is continuous rather than paroxysmal — present all day without attack-free intervals — hemicrania continua is more likely. Both are indomethacin-responsive; the distinction is the continuous vs paroxysmal pattern.
Secondary causes of PH-like headache
Pituitary tumours, posterior fossa tumours, and vascular lesions have occasionally produced PH-like headache. MRI brain at first presentation of TAC at KIMS excludes structural secondary causes.
Treatment
Management at KIMS — Indomethacin First, with Structured Alternatives When It Is Not Tolerated
A minority of PH patients cannot tolerate long-term indomethacin due to GI side effects, renal impairment, or allergy. In these cases, the following are tried at KIMS:
COX-2 Inhibitors (Celecoxib, Etoricoxib)
Better GI tolerability than indomethacin. Evidence in individual cases but not as robust as indomethacin. Worth a trial.
A COX-2 inhibitor (celecoxib 200–400mg/day or etoricoxib 60–90mg/day) is the most rational alternative when indomethacin is not tolerated — same anti-prostaglandin mechanism but far better GI tolerability. Some PH patients achieve complete attack control on a COX-2 inhibitor.
Verapamil — Partial Benefit in Selected Patients
Less effective than indomethacin for PH but has been used with partial benefit. Considered at KIMS as part of the indomethacin-intolerant pathway alongside COX-2 inhibitors and other oral alternatives.
Topiramate and Melatonin
Topiramate: Some evidence in indomethacin-intolerant PH.
Melatonin: Case reports of benefit, particularly for nocturnal attacks.
Greater Occipital Nerve Block — Bridging Therapy
Used at KIMS as a bridge when indomethacin needs to be interrupted (e.g., perioperatively or during GI complication management). Provides temporary attack suppression while GI issues are managed and longer-term pharmacological options are reconsidered.
Related Conditions
Paroxysmal Hemicrania belongs to the family of headache and pain syndromes — and the Trigeminal Autonomic Cephalalgias (TACs) — evaluated and managed at KIMS Neuroscience:
FAQs
Frequently Asked Questions
Twenty attacks a day of severe eye pain, streaming tears, runny nose. Eight months without a correct diagnosis. One tablet — indomethacin — that stops every attack within 48 hours. Paroxysmal hemicrania is diagnosable and curable at KIMS Neuroscience, Hyderabad.
At KIMS Neuroscience, Secunderabad, Hyderabad, paroxysmal hemicrania is identified by careful TAC differentiation (against cluster headache, SUNCT/SUNA, and hemicrania continua), confirmed by the supervised indomethacin test (75 → 150 → 225mg/day if needed), and managed long-term with mandatory PPI co-prescription, annual renal and BP monitoring, and a structured alternative pathway (COX-2 inhibitors, verapamil, topiramate, melatonin, and greater occipital nerve block) for the minority who cannot tolerate indomethacin. Call 040-44885000.
International enquiries: info@kimsneurosciences.com